Giralt S; Stadtmauer EA; Harousseau JL; Palumbo A; Bensinger W; Comenzo RL; Kumar S; Munshi NC; Dispenzieri A; Kyle R; Merlini G; San Miguel J; Ludwig H; Hajek R; Jagannath S; Blade J; Lonial S; Dimopoulos MA; Einsele H; Barlogie B; Anderson KC; Gertz M; Attal M; Tosi P; Sonneveld P; Boccadoro M; Morgan G; Sezer O; Mateos MV; Cavo M; Joshua D; Turesson I; Chen W; Shimizu K; Powles R;
Richardson PG; Niesvizky R; Rajkumar SV; Durie BG; IMWG., International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)., «LEUKEMIA», 2009, 23(10), pp. 1904 - 1912 [articolo]
Kumar S; Giralt S; Stadtmauer EA; Harousseau JL; Palumbo A; Bensinger W; Comenzo RL; Lentzsch S; Munshi N; Niesvizky R; San Miguel J; Ludwig H; Bergsagel L; Blade J; Lonial S; Anderson KC; Tosi P; Sonneveld P; Sezer O; Vesole D; Cavo M; Einsele H; Richardson PG; Durie BG; Rajkumar SV; International Myeloma Working Group., Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens., «BLOOD», 2009, 114(9), pp. 1729 - 1736 [articolo]
Cavo M; Di Raimondo F; Zamagni E; Patriarca F; Tacchetti P; Casulli AF; Volpe S; Perrone G; Ledda A; Ceccolini M; Califano C; Bigazzi C; Offidani M; Stefani P; Ballerini F; Fiacchini M; de Vivo A; Brioli A; Tosi P; Baccarani M., Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma., «JOURNAL OF CLINICAL ONCOLOGY», 2009, 27(30), pp. 5001 - 5007 [articolo]
Rapezzi C; Merlini G; Quarta CC; Riva L; Longhi S; Leone O; Salvi F; Ciliberti P; Pastorelli F; Biagini E; Coccolo F; Cooke RM; Bacchi-Reggiani L; Sangiorgi D; Ferlini A; Cavo M; Zamagni E; Fonte ML; Palladini G; Salinaro F; Musca F; Obici L; Branzi A; Perlini S., Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types., «CIRCULATION», 2009, 13, pp. 1203 - 1212 [articolo]
Cavo M; Pantani L; Tacchetti P; Pallotti MC; Brioli A; Petrucci A; Zamagni E; Tosi P., Thalidomide maintenance in multiple myeloma: certainties and
controversies., «JOURNAL OF CLINICAL ONCOLOGY», 2009, 27(32), pp. 186 - 187 [replica/breve intervento]
Cavo M.; Zamagni E.; Tacchetti P.; Brioli A.; Pallotti C.; Pantani L.; Ceccolini M.; Petrucci A.; Testoni N.; Terragna C.; Marzocchi G.; Durante S.; Tosi P.; Baccarani M., The road to cure in multiple myeloma: Incorporation of novel agents into autologous stem cell transplantation, «HEMATOLOGY MEETING REPORTS», 2009, 3, pp. 24 - 25 [articolo]
Terpos E; Sezer O; Croucher PI; García-Sanz R; Boccadoro M; San Miguel J; Ashcroft J; Bladé J; Cavo M; Delforge M; Dimopoulos MA; Facon T; Macro M; Waage A; Sonneveld P; European Myeloma Network., The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network., «ANNALS OF ONCOLOGY», 2009, 20(8), pp. 1303 - 1317 [articolo]
Nanni C; Rubello D; Zamagni E; Castellucci P; Ambrosini V; Montini G; Cavo M; Lodi F; Pettinato C; Grassetto G; Franchi R; Gross MD; Fanti S., 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone., «IN VIVO», 2008, 22, pp. 513 - 517 [articolo]
San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M,Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM,Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG; VISTA Trial Investigators [..; Cavo M; ..], Bortezomib plus melphalan and prednisone for initial treatment of multiple
myeloma., «THE NEW ENGLAND JOURNAL OF MEDICINE», 2008, 359, pp. 906 - 917 [articolo]
Tosi P; Terragna C; Testoni N; Zamagni E; Renzulli M; Tacchetti P; Montanari E; Perrone G; Ceccolini M; Brioli A; Pallotti MC; Tura S; Baccarani M; Cavo M., Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation., «EUROPEAN JOURNAL OF HAEMATOLOGY», 2008, 80, pp. 31 - 36 [articolo]
Rapezzi C; Riva L; Quarta CC; Perugini E; Salvi F; Longhi S; Ciliberti P;
Pastorelli F; Biagini E; Leone O; Cooke RM; Bacchi-Reggiani L; Ferlini A; Cavo M; Merlini G; Perlini S; Pasquali S; Branzi A, Gender-related risk of myocardial involvement in systemic amyloidosis, «AMYLOID», 2008, 15(1), pp. 40 - 48 [articolo]
Ludwig H; Durie BG; Bolejack V; Turesson I; Kyle RA; Blade J; Fonseca R;
Dimopoulos M; Shimizu K; San Miguel J; Westin J; Harousseau JL; Beksac M;
Boccadoro M; Palumbo A; Barlogie B; Shustik C; Cavo M; Greipp PR; Joshua D; AttalM; Sonneveld P; Crowley J., Myeloma in patients younger than age 50 years presents with more favorable
features and shows better survival: an analysis of 10 549 patients from the
International Myeloma Working Group., «BLOOD», 2008, 115, pp. 4039 - 4047 [articolo]
Palumbo A; Bringhen S; Liberati AM; Caravita T; Falcone A; Callea V; MontanaroM; Ria R; Capaldi A; Zambello R; Benevolo G; Derudas D; Dore F; Cavallo F; Gay F;Falco P; Ciccone G; Musto P; Cavo M; Boccadoro M., Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial, «BLOOD», 2008, 112, pp. 3107 - 3114 [articolo]
Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, JoshuaD, Sezer O, Ludwig H, Vesole D, Bladé J, Kyle R, Westin J, Weber D, Bringhen S,Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ,Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA;International Myeloma Working Group., Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma., «LEUKEMIA», 2008, 22, pp. 414 - 423 [articolo]
Cavo M.; Pallotti M.C.; Pantani L.; Petrucci A.; Brioli A.; Terragna C.; Testoni N.; Marzocchi G.; Durante S.; Ceccolini M.; Perrone G.; Tacchetti P.; Zamagni E.; Tosi P.; Baccarani M., Proteasome inhibitors: Bortezomib in multiple myeloma, «HEMATOLOGY MEETING REPORTS», 2008, 2, pp. 127 - 132 [articolo]
